Akums Drugs & Pharmaceuticals Ltd, established in 2004 as India’s leading pharmaceutical CDMO offering comprehensive product development and manufacturing services across formulations, reported lower profitability for Q2FY26.
Financial Highlights:
- Revenues declined 1.45% year-on-year to ₹1,018 crore from ₹1,033 crore, with CDMO up 0.7% to ₹804 crore but API/international formulations down.
- Total expenses rose 2.61% to ₹984 crore from ₹959 crore.
- Consolidated net profit fell 35.82% to ₹43 crore from ₹67 crore, with EBITDA at ₹94 crore (9.3% margin).
- Earnings per share dropped 37.44% to ₹2.59 from ₹4.14.
Challenges from API price weakness and flat volumes impacted performance despite domestic formulations growth of 5.3%.
Outlook:
Akums Drugs & Pharmaceuticals Ltd focuses on branded exports (Dapagliflozin to Switzerland), EU-GMP expansion, and domestic growth to improve margins and shareholder value.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,